Lassa Virus (LASV) Research Reagents — Antibodies & Recombinant Proteins

Glycoprotein Complex (GPC / GP1 / GP2) — Primary Neutralization Target
GPC is the sole surface antigen on LASV virions. It is synthesized as a precursor that is cleaved by SKI-1/S1P protease into GP1 (receptor binding via α-dystroglycan and LAMP1) and GP2 (class I fusion peptide). Anti-GPC neutralizing antibodies are the basis for Lassa fever therapeutic antibody development. abinScience provides the most extensive anti-LASV GPC antibody panel available:
• Biosimilar-grade reference antibody: Arevirumab-3 (VK453016) — sequence-identical to a component of the Arevirumab cocktail in clinical development
• InVivoMAb: LAVA01 (VK453010) — low-endotoxin, azide-free for in vivo neutralization studies
• 17 recombinant anti-GPC clones from human survivor-derived panels — ideal for epitope mapping, competition binning, and combination therapy screening: Fab 37.7 (VK453013), 37.2G (VK453023), 8.11G (VK453033), 9.8A (VK453043), 10.4B (VK453053), 12.1F (VK453063), 18.5C (VK453073), 19.7E (VK453083), 2.9D (VK453093), 25.10C (VK453103), 25.6A (VK453113), 36.1F (VK453123), 36.9F (VK453133), 37.2D (VK453143), 37.7F (VK453153), 8.9F (VK453163), and NE13 (VK453173)
• Recombinant GPC proteins: GPC N-His&C-TwinStrep (VK453011) (stabilized prefusion trimer), GPC N-His (VK453012), and GPC N-His variant (VK453022)
• Polyclonal antibodies: anti-GPC pAb (VK453014) and VK453024

Z Protein (Matrix / RING Domain)
Z is a small RING-domain protein that drives LASV budding by recruiting the ESCRT machinery, analogous to VP40 in filoviruses. Z is also an IFN antagonist and a potential antiviral drug target (budding inhibitors). Available: recombinant Z proteins in three formats — N-His-SUMO (VK810012), N-GST&C-His (VK810052), N-His (VK810062) — and polyclonal antibodies VK810014, VK810054, and VK810064.

RdRp / L Protein (RNA Polymerase)
L protein is the large RNA-dependent RNA polymerase responsible for genome replication and transcription, and a target for broad-spectrum arenavirus antivirals (favipiravir/T-705 inhibits L activity). Available: recombinant L protein fragments — N-His (VK810022) and N-His variant (VK810042) — and polyclonal antibodies VK810024 and VK810044.

Nucleoprotein (NP)
NP encapsidates the viral RNA genome and possesses a unique 3'-5' exonuclease domain that degrades immunostimulatory dsRNA to suppress innate immunity. NP is the primary target for antigen-capture diagnostics. Available: recombinant NP protein N-His&C-His (VK810032) and anti-NP polyclonal antibody (VK810034).

Why do you have so many anti-GPC antibody clones?
LASV GPC is a challenging target — natural LASV infection induces relatively weak neutralizing antibody responses compared to other hemorrhagic fever viruses. Having a panel of 17 clones targeting different GPC epitopes enables researchers to identify synergistic antibody combinations for therapeutic cocktail development, map neutralization-sensitive epitopes, and evaluate cross-lineage breadth (LASV has four major lineages with significant GP1 sequence divergence).

Can I work with these reagents at BSL-2?
Yes. All abinScience LASV products are recombinant proteins and antibodies — no live or inactivated virus material. Standard BSL-1/BSL-2 laboratory conditions are sufficient. Live LASV requires BSL-4 containment, but our recombinant reagents bypass this requirement entirely.

Do you have reagents for other arenaviruses?
Yes. See our LCMV (Lymphocytic choriomeningitis virus) reagents on the LCMV page, Junin virus on the JUNV page, and Lujo virus on the LUJV page. Cross-reactive reagents between Old World (LASV, LCMV) and New World (JUNV, MACV) arenaviruses are available — contact us for cross-reactivity data.

Explore reagents for related arenaviruses and hemorrhagic fever viruses:

Lassa (LASV) ✓ LCMV Junin (JUNV) Lujo (LUJV) Ebola (EBOV) Marburg (MARV) CCHFV Rift Valley fever (RVFV)